Skip to Main Content
Home Books Williams Manual of Hematology, 8e

Chapter 84: Hemostatic Dysfunction Related to Liver Diseases

  • Sections
  • Print
  • Get Citation

    Citation

    AMA Citation
    Hemostatic Dysfunction Related to Liver Diseases. In: Lichtman MA, Kaushansky K, Kipps TJ, Prchal JT, Levi MM. Lichtman M.A., Kaushansky K, Kipps T.J., Prchal J.T., Levi M.M. Eds. Marshall A. Lichtman, et al.eds. Williams Manual of Hematology, 8e New York, NY: McGraw-Hill; . http://hemonc.mhmedical.com/content.aspx?bookid=1783&sectionid=121723754. Accessed February 21, 2019.
    MLA Citation
    . "Hemostatic Dysfunction Related to Liver Diseases." Williams Manual of Hematology, 8e Lichtman MA, Kaushansky K, Kipps TJ, Prchal JT, Levi MM. Lichtman M.A., Kaushansky K, Kipps T.J., Prchal J.T., Levi M.M. Eds. Marshall A. Lichtman, et al. New York, NY: McGraw-Hill, , http://hemonc.mhmedical.com/content.aspx?bookid=1783&sectionid=121723754.

    Download citation file:

    RIS (Zotero)
    EndNote
    BibTex
    Medlars
    ProCite
    RefWorks
    Reference Manager
    Mendeley
    © Copyright
  • Tools
  • Search Book
  • Clip
Top

PATHOGENESIS

  • Loss of hepatic parenchymal cells leads to decreased plasma levels of all plasma coagulation factors except factor VIII and von Willebrand factor.

  • Thrombocytopenia occurs frequently and is usually a result of splenic sequestration (see Chap. 74), but may also be caused by an autoimmune mechanism, disseminated intravascular coagulation (DIC), folic acid deficiency, and decreased platelet production. In some patients, thrombocytopenia due to thrombopoietin (TPO) deficiency and platelet dysfunction contribute to the hemostatic abnormalities.

  • Enhanced fibrinolysis is common, and appears to be caused by complex pathogenetic mechanisms, including release and impaired clearance of plasminogen activators.

  • Dysfibrinogenemia is relatively frequently found in patients with chronic liver disease.

  • Patients with chronic liver disease may develop DIC.

CLINICAL FEATURES

  • Patients with chronic liver disease may present with purpura, epistaxis, gingival bleeding, and/or menorrhagia.

  • Bleeding may follow trauma or surgical procedures, especially in sites with high fibrinolytic activity, such as the urogenital tract or oral mucosa.

  • Patients with acute viral or toxic hepatitis usually develop abnormal bleeding only if the disease is fulminant.

  • Bleeding from esophageal varices requires primary attention to the bleeding site as well as efforts to correct the hemostatic abnormalities.

  • The coagulopathy of liver disease may also predispose the patient to thromboembolic complications.

LABORATORY FEATURES

  • Table 84–1 summarizes the laboratory abnormalities that can be found in patients with chronic liver disease. These abnormalities may both contribute to bleeding or thrombosis.

  • Determination of plasma levels of factors V, VII, and VIII may help differentiate liver disease (factor VIII levels normal or increased; factors V and VII decreased), vitamin K deficiency (factor VII decreased; factors V and VIII normal), and DIC (all decreased).

TABLE 84–1ALTERATIONS IN THE HEMOSTATIC SYSTEM IN PATIENTS WITH LIVER DISEASE THAT CONTRIBUTE TO BLEEDING (LEFT) OR COUNTERACT BLEEDING (RIGHT)
View Table|Favorite Table|Download (.pdf)
TABLE 84–1 ALTERATIONS IN THE HEMOSTATIC SYSTEM IN PATIENTS WITH LIVER DISEASE THAT CONTRIBUTE TO BLEEDING (LEFT) OR COUNTERACT BLEEDING (RIGHT)
Changes That Impair Hemostasis Changes That Promote Hemostasis
Thrombocytopenia Elevated levels of VWF
Platelet function defects Decreased levels of ADAMTS-13
Enhanced production of nitric oxide and prostacyclin Elevated levels of factor VIII
Low levels of factors II, V, VII, IX, X, and XI Decreased levels of protein C, protein S, antithrombin, and heparin cofactor II
Vitamin K deficiency Low levels of plasminogen
Dysfibrinogenemia
Low levels of α2-antiplasmin, factor XIII, and TAFI
Elevated t-PA levels

VWF, von Willebrand factor; ADAMTS-13, a disintegrin-like and metalloprotease with thrombospondin domain 13; TAFI, thrombin-activatable fibrinolysis inhibitor; t-PA, tissue type plasminogen activator.

Source: Williams Hematology, 8th ed, Chap. 129, Table 129–1, p. 2096.

THERAPY

  • Correction of coagulation is only required in case of bleeding or when an invasive procedure has to be performed.

  • Replacement of all the deficient coagulation factors may be attempted with fresh-frozen plasma, but large volumes ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close